Pharmaceutical - AstraZeneca, Diabetes

Filter

Current filters:

AstraZenecaDiabetes

Popular Filters

1 to 25 of 38 results

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

US FDA approves AstraZeneca’s Xigduo XR

US FDA approves AstraZeneca’s Xigduo XR

30-10-2014

The US Food and Drug Administration has approved Anglo-Swedish pharma major AstraZeneca’s once-daily…

AstraZenecaDiabetesPharmaceuticalRegulationUSAXigduo XR

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

24-09-2014

UK-based pharma major AstraZeneca has announced new research showing that Byetta (exenatide) added to…

AstraZenecaByettaDiabetesGlucagonPharmaceuticalResearchUK

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

30-05-2014

Anglo-Swedish pharma major AstraZeneca has announced that Bydureon (exenatide once-weekly injection)…

Anti-diabetic drugsAstraZenecaBydureonDiabetesGlucagonPharmaceuticalResearchUK

Negative IQWiG view on AstraZeneca’s combo diabetes drug Xigduo

16-05-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

AstraZenecaDiabetesGermanyPharmaceuticalPricingRegulationXigduo

Japanese approval for Forxiga and Lonsurf

24-03-2014

Anglo-Swedish drug major AstraZeneca says that Japanese Ministry of Health, Labor and Welfare approved…

Asia-PacificAstraZenecaDiabetesForxigaJapanLonsurfOncologyOno PharmaceuticalOtsukaPharmaceuticalRegulationTaiho Pharmaceutical

AstraZeneca’s diabetes drug Xigduo launched in UK

AstraZeneca’s diabetes drug Xigduo launched in UK

11-03-2014

Anglo-Swedish drug major AstraZeneca’s type 2 diabetes drug Xigduo is now available in the UK.

AstraZenecaDiabetesPharmaceuticalRegulationUKXigduo

FDA approves Bydureon Pen for type 2 diabetes

FDA approves Bydureon Pen for type 2 diabetes

03-03-2014

Anglo-Swedish drug major AstraZeneca says the US Food and Drug Administration has approved the Bydureon…

AlkermesAmylinAstraZenecaBristol-Myers SquibbBydureonDiabetesPharmaceuticalRegulationUSA

FDA to review heart failure risk with AstraZeneca diabetes drug

FDA to review heart failure risk with AstraZeneca diabetes drug

12-02-2014

The US Food and Drug Administration has requested clinical trial data from Anglo-Swedish drug major AstraZeneca,…

AstraZenecaDiabetesKombiglyzeNorth AmericaOnglyzaPharmaceuticalRegulationResearchUSA

AstraZeneca’s fixed-dose diabetes drug Xigduo approved in Europe

AstraZeneca’s fixed-dose diabetes drug Xigduo approved in Europe

22-01-2014

The European Commission has approved Anglo-Swedish drug major AstraZeneca and soon to be ex-partner USA-based…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesPharmaceuticalRegulationXigduo

US FDA approves AstraZeneca’s Farxiga to treat type 2 diabetes

US FDA approves AstraZeneca’s Farxiga to treat type 2 diabetes

09-01-2014

Reversing a previous 2012 negative decision, the US Food and Drug Administration yesterday approved Anglo-Swedish…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesFarxigaNorth AmericaPharmaceuticalRegulationUSA

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

19-12-2013

Confirming recent runors, Anglo-Swedish drug major AstraZeneca revealed this morning that it will acquire…

AstraZenecaBristol-Myers SquibbDiabetesExenatide InjectionMergers & AcquisitionsOnglyzaPharmaceutical

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

14-12-2013

Drug majors Bristol-Myers Squibb and AstraZeneca have reportedly decided to stop marketing their diabetes…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaMarkets & MarketingPharmaceuticalPricing

Strong FDA advisory panel backing for Bristol-Myers/AstraZeneca’s diabetes drug

Strong FDA advisory panel backing for Bristol-Myers/AstraZeneca’s diabetes drug

13-12-2013

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesForxigaNorth AmericaPharmaceuticalRegulation

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

05-12-2013

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

AstraZenecaBristol-Myers SquibbDiabetesEuropeOnglyzaPharmaceuticalPricingRegulation

New hypoglycemia and pancreatitis sub-analyses from the Onglyza SAVOR study released at EASD

New hypoglycemia and pancreatitis sub-analyses from the Onglyza SAVOR study released at EASD

27-09-2013

Bristol-Myers Squibb and partner AstraZeneca have announced additional results from the SAVOR cardiovascular…

AstraZenecaBristol-Myers SquibbDiabetesOnglyzaPharmaceuticalResearch

Growth drivers for China's type 2 diabetes market

09-08-2013

The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

EU regulator finds no added pancreatic risks for GLP-1 diabetes drugs

26-07-2013

Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbBydureonDiabetesEli LillyEuropeJanuviaMerck & CoNovo NordiskOnglyzaPharmaceuticalRegulationTradjentaVictoza

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

19-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research

17-06-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

1 to 25 of 38 results

Back to top